Published in Circ Res on June 10, 2011
Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol (2012) 1.66
Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid Redox Signal (2012) 1.60
Fibrocalcific aortic valve disease: opportunity to understand disease mechanisms using mouse models. Circ Res (2013) 1.09
Mechanisms of arterial calcifications and consequences for cardiovascular function. Kidney Int Suppl (2011) (2013) 0.93
ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation. Free Radic Biol Med (2014) 0.91
Blunted temporal activity of microvascular perfusion heterogeneity in metabolic syndrome: a new attractor for peripheral vascular disease? Am J Physiol Heart Circ Physiol (2012) 0.91
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptor β mediating nitric oxide production and NF-κB suppression in endothelial cells. Cell Death Dis (2013) 0.86
Aortic valve sclerosis in mice deficient in endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol (2014) 0.83
Positron emission tomography of the vulnerable atherosclerotic plaque in man--a contemporary review. Clin Physiol Funct Imaging (2013) 0.80
Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. J Lipid Res (2015) 0.79
2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε. Amino Acids (2012) 0.79
Policosanol as a new inhibitor candidate for vascular calcification in diabetic hyperlipidemic rats. Exp Biol Med (Maywood) (2016) 0.79
Reactive Oxygen Species (ROS) Mediate p300-dependent STAT1 Protein Interaction with Peroxisome Proliferator-activated Receptor (PPAR)-γ in CD36 Protein Expression and Foam Cell Formation. J Biol Chem (2015) 0.78
Losartan Inhibits Nuclear Factor-κB Activation Induced by Small, Dense LDL Cholesterol Particles in Human Umbilical Vein Endothelial Cells. Curr Ther Res Clin Exp (2013) 0.78
Chronic kidney disease: the "perfect storm" of cardiometabolic risk illuminates genetic diathesis in cardiovascular disease. J Am Coll Cardiol (2013) 0.75
ROS via BTK-p300-STAT1-PPARγ signaling activation mediates cholesterol crystals-induced CD36 expression and foam cell formation. Redox Biol (2016) 0.75
The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury. J Cardiovasc Pharmacol Ther (2015) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 13.53
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest (1991) 6.50
Bone formation and inflammation in cardiac valves. Circulation (2001) 6.01
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol (2007) 5.50
Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest (1993) 4.54
A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res (2007) 4.34
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
Vascular calcification: pathobiology of a multifaceted disease. Circulation (2008) 3.64
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem (1995) 3.19
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation (2002) 3.01
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2001) 2.93
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol (1997) 2.80
Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med (2001) 2.79
RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun (1998) 2.62
Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem (2008) 2.55
Chondrogenic and adipogenic potential of microvascular pericytes. Circulation (2004) 2.48
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest (1994) 2.43
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb (1994) 2.31
Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem (1993) 2.27
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol (2004) 2.23
Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol (2007) 2.22
Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation (2000) 2.22
Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res (2002) 2.22
Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation (2009) 2.20
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Multilineage potential of cells from the artery wall. Circulation (2003) 2.17
RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res (2009) 2.17
Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol (2003) 2.15
Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab (2001) 2.14
Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem (1998) 2.10
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02
Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol (2010) 1.95
Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation (2010) 1.93
Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol (2002) 1.88
Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol (2000) 1.87
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol (2006) 1.86
Mesoangioblasts--vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev (2003) 1.80
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol (2001) 1.77
Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol (1999) 1.75
Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem (1999) 1.75
Monocyte/macrophage regulation of vascular calcification in vitro. Circulation (2002) 1.67
Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64
Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun (1998) 1.63
Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells. Atherosclerosis (2010) 1.62
PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res (2003) 1.61
Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol (1992) 1.60
Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol (2003) 1.56
Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res (2001) 1.55
A novel molecular mechanism modulating osteoclast differentiation and function. Bone (1999) 1.51
Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem (2009) 1.50
In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature (1986) 1.50
Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab (2003) 1.46
Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J (2010) 1.46
Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res (2010) 1.45
Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) (2010) 1.44
Vascular calcification and bone disease: the calcification paradox. Trends Mol Med (2009) 1.44
Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem (2003) 1.40
Do statins slow the progression of aortic valve stenosis? Interact Cardiovasc Thorac Surg (2008) 1.40
Pericytes derived from the retinal microvasculature undergo calcification in vitro. J Cell Sci (1990) 1.40
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol (2001) 1.38
Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int (2003) 1.37
Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab (2004) 1.35
Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol (2009) 1.35
Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2003) 1.34
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun (1998) 1.33
Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol (2007) 1.33
Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J (2002) 1.32
Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int (2003) 1.29
8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem (2002) 1.26
Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem (1999) 1.24
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology (2003) 1.24
Genetic determination of cartilaginous metaplasia in mouse aorta. Arterioscler Thromb Vasc Biol (1995) 1.24
Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood (2010) 1.23
High-density lipoprotein regulates calcification of vascular cells. Circ Res (2002) 1.22
Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell (2010) 1.21
Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res (1999) 1.21
The missing bone. Cell (1997) 1.20
Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med (1983) 1.20
N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res (2006) 1.17
Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res (2010) 1.17
Lipid hypothesis of cardiovascular calcification. Circulation (1997) 1.15
Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery (1980) 1.14
Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis (2008) 1.13
Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int (2008) 1.12
Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol (2004) 4.02
Vascular calcification: pathobiology of a multifaceted disease. Circulation (2008) 3.64
Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int (2010) 2.61
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
Regulatory mechanisms in vascular calcification. Nat Rev Cardiol (2010) 2.22
Pitting phosphate transport inhibitors against vascular calcification. Circ Res (2006) 1.59
Pattern formation by vascular mesenchymal cells. Proc Natl Acad Sci U S A (2004) 1.54
Mesenchymal stem cells and the artery wall. Circ Res (2004) 1.52
Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol (2011) 1.34
Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol (2003) 1.29
High-density lipoprotein regulates calcification of vascular cells. Circ Res (2002) 1.22
Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol (2014) 1.21
Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol (2007) 1.21
Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plaque vulnerability. Am J Physiol Heart Circ Physiol (2009) 1.18
Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun (2008) 1.15
Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol (2009) 1.09
Left-right symmetry breaking in tissue morphogenesis via cytoskeletal mechanics. Circ Res (2012) 1.02
Adverse effects of hyperlipidemia on bone regeneration and strength. J Bone Miner Res (2012) 1.01
Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J Bone Miner Res (2011) 1.00
Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens (2002) 1.00
Bone density and hyperlipidemia: the T-lymphocyte connection. J Bone Miner Res (2010) 0.99
Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J Biol Chem (2007) 0.98
Hyperlipidemia impairs osteoanabolic effects of PTH. J Bone Miner Res (2008) 0.96
Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Bone Miner Res (2002) 0.95
A dynamic model of calcific nodule destabilization in response to monocyte- and oxidized lipid-induced matrix metalloproteinases. Am J Physiol Cell Physiol (2011) 0.93
Vascular calcification and its relation to bone calcification: possible underlying mechanisms. J Nucl Cardiol (2003) 0.92
Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells. J Biol Chem (2011) 0.92
Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol (2008) 0.92
Mechanical response of a calcified plaque model to fluid shear force. Ann Biomed Eng (2006) 0.92
T0901317, an LXR agonist, augments PKA-induced vascular cell calcification. FEBS Lett (2009) 0.90
PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem (2010) 0.88
Role of cellular cholesterol metabolism in vascular cell calcification. J Biol Chem (2011) 0.87
The bone-vascular axis in chronic kidney disease. Curr Opin Nephrol Hypertens (2010) 0.87
Nanoscale architecture in atherosclerotic calcification. Arterioscler Thromb Vasc Biol (2008) 0.86
Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids. J Lipid Res (2009) 0.83
Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci (2012) 0.83
Patterns of periodic holes created by increased cell motility. Interface Focus (2012) 0.82
Murine models of atherosclerotic calcification. Curr Drug Targets (2008) 0.82
Atmospheric ultrafine particles promote vascular calcification via the NF-κB signaling pathway. Am J Physiol Cell Physiol (2012) 0.81
Role of paraoxonase-1 in bone anabolic effects of parathyroid hormone in hyperlipidemic mice. Biochem Biophys Res Commun (2013) 0.80
Systems biology of vascular calcification. Trends Cardiovasc Med (2009) 0.80
Return to ectopia: stem cells in the artery wall. Arterioscler Thromb Vasc Biol (2005) 0.79
Mechanisms linking osteoporosis with cardiovascular calcification. Curr Osteoporos Rep (2009) 0.79
Directing tissue morphogenesis via self-assembly of vascular mesenchymal cells. Biomaterials (2012) 0.77
The effects of hyperlipidemia on implant osseointegration in the mouse femur. J Oral Implantol (2013) 0.77
Focal high cell density generates a gradient of patterns in self-organizing vascular mesenchymal cells. J Vasc Res (2012) 0.76
Preferred mitotic orientation in pattern formation by vascular mesenchymal cells. Am J Physiol Heart Circ Physiol (2012) 0.76
The hemosteoblast: friend or foe? Circ Res (2011) 0.76
Roles of parathyroid hormone (PTH) receptor and reactive oxygen species in hyperlipidemia-induced PTH resistance in preosteoblasts. J Cell Biochem (2014) 0.76
A matter of degree: a commentary on "Influence of oxidized low-density lipoproteins (LDL) on the viability of osteoblastic cells". Free Radic Biol Med (2007) 0.75